Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27624296 | 0.85 | KMO (0.50) | KMT2A | |
| SCHEMBL1549765 | 0.82 | KMT2A (0.46) | KMT2A | |
| SCHEMBL2323369 | 0.82 | KMO (0.46) | AKR1C3AKR1C2KDM5AKDM4CKDM5B | |
| SCHEMBL3658161 | 0.80 | HNF4A (0.44) | KMT2A | |
| SCHEMBL27791060 | 0.80 | KEAP1 (0.45) | AKR1C3AKR1C2KMT2A | |
| SCHEMBL3983853 | 0.79 | HSD17B10 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27605316 | 0.79 | KMT2A (0.44) | KMT2A | |
| SCHEMBL27605323 | 0.78 | MEN1 (0.52) | AKR1C3KMT2A | |
| SCHEMBL3977097 | 0.78 | FNTA (0.46) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL27624311 | 0.76 | NQO2 (0.55) | HSD17B1HSD17B2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100543022-C | 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound | DAINIPPON PHARMACEUTICAL CO (JP) | 2009-09-23 | — | — | CN | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| CN-1628111-A | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | HPGDS 1401/4885CHRM2 56/4885CHRM4 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.